HealthStream (HSTM) Hisse Özeti
HealthStream, Inc. Amerika Birleşik Devletleri'ndeki sağlık kuruluşları için Hizmet Olarak Yazılım (SaaS) tabanlı uygulamalar sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 1/6 |
| Geçmiş Performans | 2/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
Risk kontrollerimizden HSTM için herhangi bir risk tespit edilmedi.
HSTM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
HealthStream, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$28.87 |
| 52 Haftanın En Yüksek Seviyesi | US$31.11 |
| 52 Haftanın En Düşük Seviyesi | US$19.50 |
| Beta | 0.44 |
| 1 Aylık Değişim | 6.39% |
| 3 Aylık Değişim | 21.25% |
| 1 Yıllık Değişim | 4.07% |
| 3 Yıllık Değişim | 36.70% |
| 5 Yıllık Değişim | -2.76% |
| Halka arzdan bu yana değişim | 239.65% |
Son Haberler & Güncellemeler
Recent updates
HSTM: Buybacks Updated Guidance And Cleaner Quarters Will Shape Balanced Outlook
Analysts have lifted their fair value estimate for HealthStream from $24.00 to $29.00, citing updated models following recent sector strength and the view that clearer upcoming quarters may be needed to justify further price gains. What’s in the News for HealthStream HealthStream updated 2026 guidance and now expects revenue in a range of $327.0 million to $332.0 million and net income in a range of $19.5 million to $22.2 million.
HSTM: Higher P/E Outlook And Capital Returns Will Support Future Upside
HealthStream's fair value estimate has been updated from $30.50 to $33.50 as analysts factor in a revised P/E outlook and recent price target increases that reflect adjusted expectations ahead of upcoming earnings. Analyst Commentary Recent Street research on HealthStream offers a mixed picture, with some analysts updating models and price targets ahead of upcoming earnings.HSTM: Buybacks And Updated Assumptions Will Shape Balanced Future Share Performance
Analysts have raised their price target on HealthStream by $3. They cite updated views on its fair value and revised assumptions for the discount rate, revenue growth, profit margins, and future P/E.HSTM: AI Disruption Risks And Buybacks Will Shape Future Share Performance
Analysts have raised their fair value estimate for HealthStream from $21.00 to $24.00, citing updated views on the company’s discount rate, revenue growth, profit margins, and future P/E assumptions reflected in recent Street research. Analyst Commentary Street research around HealthStream has become more mixed, even as some firms lift price targets.HSTM: AI Disruption Risks And Capital Returns Will Drive Future Share Performance
Narrative Update on HealthStream Analysts have reset their price target on HealthStream to $21 from $25, citing respectable 4Q'25 results and management's detailed response to AI-related risks. They view this as leaving the company relatively better positioned than many other SaaS peers.HSTM: AI Risk Positioning And Capital Returns Will Support Upside Potential
Analysts have reduced the fair value estimate for HealthStream from $34.00 to $30.50, citing a lower forward P/E assumption and an increased discount rate, while also referencing recent Street research that trimmed the price target to $21 and highlighted both respectable 4Q'25 results and management's case that the company is relatively well positioned against AI-related risks in SaaS. Analyst Commentary Recent Street commentary on HealthStream focuses on how the company is handling AI related risks in SaaS and what that could mean for valuation and execution.HSTM: AI Disruption Risks And Capital Returns Will Shape Future Outlook
Analysts have reset their price target on HealthStream to $21, down from $25, after incorporating fresh views on AI-related risks and management's argument that the company is relatively well positioned compared with other SaaS names. Analyst Commentary Bearish analysts have trimmed expectations on HealthStream by cutting the price target to $21 from $25, while maintaining a neutral stance on the shares.HSTM: AI Risks, Capital Returns And Fair Value Will Shape Outlook
Analysts have reduced their price target on HealthStream to $21 from $25, citing a recalibration of fair value, discount rate and future P/E assumptions, while also highlighting management's view that the business model remains relatively well positioned against rising AI related concerns for SaaS names. Analyst Commentary Bearish analysts are signaling a more cautious stance on HealthStream after the latest quarterly update.HSTM: Dividend Hike And Buyback Will Support Future Upside Potential
Analysts have kept their $25.00 price target for HealthStream unchanged, citing only slight tweaks to assumptions around the discount rate, revenue growth, profit margin, and future P/E that together do not materially shift their overall view on the stock. What's in the News The board approved a quarterly cash dividend of US$0.035 per share, a 12.9% increase from the prior US$0.031, payable on March 20, 2026, to shareholders of record on March 9, 2026 (company announcement).HSTM: Fine Tuned Assumptions Will Support Future Upside Potential
Analysts kept their fair value estimate for HealthStream at $25.00, with modest tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions. This underpins the unchanged price target and reflects only fine tuning in their models rather than a shift in overall view.HealthStream, Inc. (NASDAQ:HSTM) Investors Are Less Pessimistic Than Expected
HealthStream, Inc.'s ( NASDAQ:HSTM ) price-to-earnings (or "P/E") ratio of 28.8x might make it look like a sell right...HSTM: Share Repurchases And Acquisition Efforts Will Drive Future Upside
Analysts now place their fair value estimate for HealthStream at US$25.00. The updated target reflects small tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions in their models.HSTM: Share Buybacks And M&A Activity Will Support Future Upside
Analysts have trimmed their fair value estimate for HealthStream from US$28 to about US$25. They cite updated assumptions on discount rates, revenue growth, profit margins, and a lower future P/E multiple in their refreshed models.Earnings Beat: HealthStream, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
It's been a good week for HealthStream, Inc. ( NASDAQ:HSTM ) shareholders, because the company has just released its...A Look At The Intrinsic Value Of HealthStream, Inc. (NASDAQ:HSTM)
Key Insights Using the 2 Stage Free Cash Flow to Equity, HealthStream fair value estimate is US$29.23 With US$24.60...HealthStream: High-Quality Business At A Fair Price
Summary HealthStream boasts a resilient, founder-led SaaS business model with decades of profitable growth, strong balance sheet, and shareholder-friendly capital returns. Revenue is highly recurring and predictable due to long-term, non-cancelable contracts, with built-in price escalators and industry-leading products recognized by G2. Short-term headwinds include funding cuts, customer bankruptcy, and delayed revenue recognition, prompting a downward revision in 2025 guidance, but technical issues are seen as temporary. Transition to SaaS and platform offerings positions HealthStream for higher margins and future growth, with most products tied to essential, mandatory healthcare requirements. Despite strong fundamentals, the stock remains expensive on a P/E basis but appears fairly valued on a P/S basis; thus, I rated it as HOLD overall, with a small starter position reflecting my long-term confidence in the business. Read the full article on Seeking AlphaWe Discuss Why The CEO Of HealthStream, Inc. (NASDAQ:HSTM) Is Due For A Pay Rise
Key Insights HealthStream's Annual General Meeting to take place on 29th of May Total pay for CEO Bobby Frist includes...HealthStream (NASDAQ:HSTM) Is Doing The Right Things To Multiply Its Share Price
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...HealthStream, Inc. Just Beat EPS By 5.1%: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that HealthStream, Inc. ( NASDAQ:HSTM ) filed its yearly result this time last week...Should You Be Adding HealthStream (NASDAQ:HSTM) To Your Watchlist Today?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Returns At HealthStream (NASDAQ:HSTM) Are On The Way Up
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Typically, we'll want...
Navigating Temporary Challenges, The Company Sets Its Sights On Long-term Revenue Growth And Market Expansion
Expansion into the health plan market and strong sales pipelines in key products signal potential for revenue growth and customer base diversification.HealthStream, Inc.'s (NASDAQ:HSTM) Shareholders Might Be Looking For Exit
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...We Ran A Stock Scan For Earnings Growth And HealthStream (NASDAQ:HSTM) Passed With Ease
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Hissedar Getirileri
| HSTM | US Healthcare Services | US Pazar | |
|---|---|---|---|
| 7D | -0.2% | 2.5% | -1.5% |
| 1Y | 4.1% | -22.1% | 17.8% |
Getiri vs. Endüstri: HSTM geçen yıl % -22.1 oranında getiri sağlayan US Healthcare Services sektörünü aştı.
Getiri vs Piyasa: HSTM geçen yıl % 17.8 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| HSTM volatility | |
|---|---|
| HSTM Average Weekly Movement | 4.8% |
| Healthcare Services Industry Average Movement | 10.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: HSTM son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: HSTM 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1990 | 1,150 | Bobby Frist | www.healthstream.com |
HealthStream, Inc. Amerika Birleşik Devletleri'ndeki sağlık kuruluşları için Hizmet Olarak Yazılım (SaaS) tabanlı uygulamalar sunmaktadır. Şirket, bir teknoloji platformu olan hStream; sağlık kuruluşlarına işe alma, başvuru gönderme, lisans ve diğer kimlik bilgilerinin doğrulanması, ayrıcalık tanıma, kimliklendirme komiteleri tarafından atamalar, kayıt, ağ, yönetim, işe alım ve sağlayıcıların performans değerlendirmelerinden sağlayıcı yaşam döngüsü yönetimini destekleyen araçlar sağlayan CredentialStream; ShiftWizard; ve AI / ML odaklı klinik yetkinlik geliştirme sistemi olan Competency Suite'i sunmaktadır. Ayrıca performans değerlendirme, yetkinlik yönetimi, ifşa yönetimi, klinik yetkinlik, değerlendirme, geliştirme, simülasyon tabanlı eğitim, klinik rotasyon ve işe alım yönetimi, kalite yönetimi ve endüstri eğitimi için uygulamalar sunmaktadır.
HealthStream, Inc. Temel Bilgiler Özeti
| HSTM temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$844.16m |
| Kazançlar(TTM) | US$21.20m |
| Gelir(TTM) | US$321.12m |
HSTM aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| HSTM gelir tablosu (TTM) | |
|---|---|
| Gelir | US$321.12m |
| Gelir Maliyeti | US$112.13m |
| Brüt Kâr | US$208.99m |
| Diğer Giderler | US$187.79m |
| Kazançlar | US$21.20m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 0.73 |
| Brüt Marj | 65.08% |
| Net Kâr Marjı | 6.60% |
| Borç/Özkaynak Oranı | 0% |
HSTM uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
HSTM güvenilir bir temettü ödüyor mu?
HSTM temettü geçmişine ve kıyaslamalara bakın| HealthStream temettü tari̇hleri̇ | |
|---|---|
| Eski Temettü Tarihi | Aug 17 2026 |
| Temettü Ödeme Tarihi | Aug 28 2026 |
| Eski temettüye kadar geçen günler | 7 days |
| Temettü ödeme tarihine kadar geçen günler | 4 days |
HSTM güvenilir bir temettü ödüyor mu?
HSTM temettü geçmişine ve kıyaslamalara bakınŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/23 12:10 |
| Gün Sonu Hisse Fiyatı | 2026/08/21 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
HealthStream, Inc. 11 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Matthew Gillmor | Baird |
| Vincent Colicchio | Barrington Research Associates, Inc. |
| Richard Close | Canaccord Genuity |